Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis.

Vered Rosenberg Gabriel ChodickZhenyi XueFreddy Faccin Howard Amital

Published in: Advances in therapy (2023)

Treatment choice primarily depends on disease activity and prognosis. Real-world data, showing differences in drug survival of bDMARDs and tsDMARD, can also be used in the variety of considerations when choosing treatment. Future studies could separate patients with RA into subgroups, which would also account for potential drug survival differences and enable personalized therapy.

Keyphrases

disease activity
rheumatoid arthritis
systemic lupus erythematosus
stem cells
type diabetes
electronic health record
risk assessment
ankylosing spondylitis
machine learning
big data
climate change
human health
adverse drug